Literature DB >> 16816197

Phylogenomic and biochemical characterization of three Legionella pneumophila polypeptide deformylases.

Jianzhong Huang1, Glenn S Van Aller, Amy N Taylor, John J Kerrigan, Wu-Schyong Liu, Janice M Trulli, Zhihong Lai, David Holmes, Kelly M Aubart, James R Brown, Magdalena Zalacain.   

Abstract

Legionella pneumophila is a gram-negative facultative intracellular human pathogen that can cause fatal Legionnaires' disease. Polypeptide deformylase (PDF) is a novel broad-spectrum antibacterial target, and reports of inhibitors of PDF with potent activities against L. pneumophila have been published previously. Here, we report the identification of not one but three putative pdf genes, pdfA, pdfB, and pdfC, in the complete genome sequences of three strains of L. pneumophila. Phylogenetic analysis showed that L. pneumophila PdfA is most closely related to the commonly known gamma-proteobacterial PDFs encoded by the gene def. PdfB and PdfC are more divergent and do not cluster with any specific bacterial or eukaryotic PDF. All three putative pdf genes from L. pneumophila strain Philadelphia 1 have been cloned, and their encoded products have been overexpressed in Escherichia coli and purified. Enzymatic characterization shows that the purified PDFs with Ni2+ substituted are catalytically active and able to remove the N-formyl group from several synthetic polypeptides, although they appear to have different substrate specificities. Surprisingly, while PdfA and PdfB with Zn2+ substituted are much less active than the Ni2+ forms of each enzyme, PdfC with Zn2+ substituted was as active as the Ni2+ form for the fMA substrate and exhibited substrate specificity different from that of Ni2+ PdfC. Furthermore, the catalytic activities of these enzymes are potently inhibited by a known small-molecule PDF inhibitor, BB-3497, which also inhibits the extracellular growth of L. pneumophila. These results indicate that even though L. pneumophila has three PDFs, they can be effectively inhibited by PDF inhibitors which can, therefore, have potent anti-L. pneumophila activity.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16816197      PMCID: PMC1539947          DOI: 10.1128/JB.00866-05

Source DB:  PubMed          Journal:  J Bacteriol        ISSN: 0021-9193            Impact factor:   3.490


  33 in total

Review 1.  Peptide deformylase as a target for new generation, broad spectrum antimicrobial agents.

Authors:  C Giglione; M Pierre; T Meinnel
Journal:  Mol Microbiol       Date:  2000-06       Impact factor: 3.501

2.  Deformylase as a novel antibacterial target.

Authors:  Z Yuan; J Trias; R J. White
Journal:  Drug Discov Today       Date:  2001-09-15       Impact factor: 7.851

Review 3.  Structure-activity relationship analysis and therapeutic potential of peptide deformylase inhibitors.

Authors:  Adrien Boularot; Carmela Giglione; Isabelle Artaud; Thierry Meinnel
Journal:  Curr Opin Investig Drugs       Date:  2004-08

Review 4.  Legionnaires' disease. A review.

Authors:  P H Edelstein; R D Meyer
Journal:  Chest       Date:  1984-01       Impact factor: 9.410

5.  Slow-binding inhibition of peptide deformylase by cyclic peptidomimetics as revealed by a new spectrophotometric assay.

Authors:  Kiet T Nguyen; Xubo Hu; Dehua Pei
Journal:  Bioorg Chem       Date:  2004-06       Impact factor: 5.275

Review 6.  Legionella and Legionnaires' disease: 25 years of investigation.

Authors:  Barry S Fields; Robert F Benson; Richard E Besser
Journal:  Clin Microbiol Rev       Date:  2002-07       Impact factor: 26.132

7.  Evidence in the Legionella pneumophila genome for exploitation of host cell functions and high genome plasticity.

Authors:  Christel Cazalet; Christophe Rusniok; Holger Brüggemann; Nora Zidane; Arnaud Magnier; Laurence Ma; Magalie Tichit; Sophie Jarraud; Christiane Bouchier; François Vandenesch; Frank Kunst; Jérôme Etienne; Philippe Glaser; Carmen Buchrieser
Journal:  Nat Genet       Date:  2004-10-03       Impact factor: 38.330

8.  Oral anti-pneumococcal activity and pharmacokinetic profiling of a novel peptide deformylase inhibitor.

Authors:  M Gross; J Clements; R P Beckett; W Thomas; S Taylor; D Lofland; S Ramanathan-Girish; M Garcia; S Difuntorum; U Hoch; H Chen; K W Johnson
Journal:  J Antimicrob Chemother       Date:  2004-02-12       Impact factor: 5.790

9.  Characterization of a human peptide deformylase: implications for antibacterial drug design.

Authors:  Kiet T Nguyen; Xubo Hu; Craig Colton; Ratna Chakrabarti; Michael X Zhu; Dehua Pei
Journal:  Biochemistry       Date:  2003-08-26       Impact factor: 3.162

10.  Control of peptide deformylase activity by metal cations.

Authors:  S Ragusa; S Blanquet; T Meinnel
Journal:  J Mol Biol       Date:  1998-07-17       Impact factor: 5.469

View more
  5 in total

1.  Microbiome changes in healthy volunteers treated with GSK1322322, a novel antibiotic targeting bacterial peptide deformylase.

Authors:  Seda Arat; Aaron Spivak; Stephanie Van Horn; Elizabeth Thomas; Christopher Traini; Ganesh Sathe; George P Livi; Karen Ingraham; Lori Jones; Kelly Aubart; David J Holmes; Odin Naderer; James R Brown
Journal:  Antimicrob Agents Chemother       Date:  2014-12-08       Impact factor: 5.191

2.  In vitro and intracellular activities of peptide deformylase inhibitor GSK1322322 against Legionella pneumophila isolates.

Authors:  Jacques Dubois; Maïtée Dubois; Jean-François Martel; Kelly Aubart; Deborah Butler
Journal:  Antimicrob Agents Chemother       Date:  2014-10-27       Impact factor: 5.191

3.  Identification of crucial amino acids of bacterial Peptide deformylases affecting enzymatic activity in response to oxidative stress.

Authors:  Sanjay Kumar; Pavitra Kanudia; Subramanian Karthikeyan; Pradip K Chakraborti
Journal:  J Bacteriol       Date:  2013-10-18       Impact factor: 3.490

4.  Ligand and Structure-Based Approaches for the Identification of Peptide Deformylase Inhibitors as Antibacterial Drugs.

Authors:  Jian Gao; Li Liang; Yasheng Zhu; Shengzhi Qiu; Tao Wang; Ling Zhang
Journal:  Int J Mol Sci       Date:  2016-07-15       Impact factor: 5.923

5.  The C-terminal residue of phage Vp16 PDF, the smallest peptide deformylase, acts as an offset element locking the active conformation.

Authors:  Renata Grzela; Julien Nusbaum; Sonia Fieulaine; Francesco Lavecchia; Willy V Bienvenut; Cyril Dian; Thierry Meinnel; Carmela Giglione
Journal:  Sci Rep       Date:  2017-09-08       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.